When treating refractory kidney cancer, clinicians prioritize regimens offering the most durable initial response. They argue against “saving” effective drugs for later, as disease progression is traumatic for patients and many never successfully receive subsequent lines of therapy. The goal is long-term disease control now, not preserving theoretical future options.

Lurbinectedin's effectiveness in second-line SCLC is highly dependent on the chemotherapy-free interval after first-line treatment. Patients with a longer interval (>90 days) show significantly better response rates and disease control, reinforcing that "platinum sensitivity" acts as a proxy for broader cytotoxic drug sensitivity.

To avoid committing young patients to lifelong daily medication, oncologists treating desmoid tumors with oral agents will consider "treatment holidays." After achieving maximum response, they may pause therapy and restart only upon symptomatic progression, balancing efficacy with quality of life.

Despite promising trial data for Tarlatumab in first-line small cell lung cancer, its clear survival benefit as a second-line therapy makes clinicians reluctant to lose it as a reliable later-stage option. This creates a strategic dilemma about the optimal timing to deploy the most effective new therapies.

While lurbinectedin initially improves survival outcomes as maintenance therapy, long-term data shows the survival curves eventually converge. Experts interpret this to mean the drug provides a temporary, additive chemotherapy-like effect rather than a true synergy with immunotherapy that would produce a durable response and separate the "tails of the curves."

The IMFORTE trial saw a 25% attrition rate between induction and randomization for maintenance therapy. This reflects the clinical reality that a significant portion of patients are too debilitated by initial chemo-IO to be candidates for intensified maintenance, making immunotherapy alone a reasonable alternative for them.

Beyond rigid trial protocols, a flexible approach to first-line T-DXd is practical and patient-centered. This includes discussing treatment breaks for holidays or switching to a less burdensome maintenance regimen (like subcutaneous HP) if a patient is tired of frequent clinic visits, prioritizing their quality of life.

To mitigate long-term toxicity from TDXD, oncologists are proposing an "induction/maintenance" approach. Patients receive TDXD for an initial period to achieve maximal response, then switch to a less toxic maintenance regimen for a "chemotherapy holiday," improving quality of life.

Since the IMFORTE trial excluded patients with brain metastases, oncologists hold differing views. Some are purists and avoid it off-protocol, while others explain the lack of evidence (which isn't negative evidence) to the patient and consider it, especially if CNS disease is controlled, creating a personalized decision-making scenario.